Teva Pharmaceutical Industries Limited (TEVA) Release: Pride-HD Study Enrolling Patients Globally To Further Evaluate Pridopidine For The Symptomatic Treatment Of Huntington’s Disease
4/24/2014 9:37:58 AM
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today enrollment of the first patient in The Pride-HD study, a phase II, randomized, double-blind, placebo-controlled global study designed to evaluate the impact of pridopidine, an investigational medication, on motor impairment in patients with Huntington’s disease (HD).
Help employers find you! Check out all the jobs and post your resume.
comments powered by